The human genome is comprised of billions of points of tiny genetic code. DNA sequencing enables researchers to decode these DNA fragments, helping uncover valuable genetic information that relates to our well-being. Until recently, though, the technology didn’t exist to accurately and quickly process, decode and analyze the human genome. In the last decade, DNA sequencing has been completely revolutionized.
Today, Next Generation Sequencing (NGS) technology has made it possible to process and decode the entire human genome in as little as few days, where the older Sanger sequencing technology once took more than a decade to deliver the same results. NGS technology applications enable unprecedented scalability and touch on all areas of DNA research, including whole genome sequencing and exome sequencing. These contemporary sequencing methods are much more sensitive, enabling clinicians and researchers alike to discover a greater volume of submicroscopic genetic mutations in our DNA.
NGS platforms are able to sequence millions of small fragments of DNA in parallel. Researchers can choose a wide view to look at multiple samples, or zoom in for an in-depth analysis of a small, specific area of interest. Massive amounts of DNA sequencing data can be generated quicker, and more cost-effective than ever before.
NGS is the future of DNA research, and the applications for this technology have the potential for enhancing individualized patient care. Costs are going down, and the rate at which we are able to sequence DNA is rapidly increasing. This combination means the most cutting-edge technology is accessible to more researchers. You are now able to efficiently compare the DNA of thousands of people, exploring the individual genes that cause things like cancer, schizophrenia, and autism.
NGS applications include:
While the traditional Sanger sequencing only captures substitutions and small insertions and deletions, next-gen sequencing captures a wider range of substitutions, insertions, and deletions of DNA, as well as rearrangements such as inversions and translocations. Instead of only being able to investigate genes that we already know about, NGS allows us to discover brand new mutations and disease-causing genes.
NGS technology is even helping researchers define the genomes of pathogens that may contain details about drug sensitivities, and has been used to track outbreaks. It is completely changing the way researchers approach problems, uncovering exciting, unprecedented solutions.
Taking advantage of NGS requires some extra computer capacity and the expertise to be able to understand all the new data acquired. Clinics may not have the resources, but we do.
For more than 20 years, Macrogen Corp. has provided a wide variety of genetic technology services to more than 100 countries.
Macrogen, Inc. was founded in 1997, and in 2005, Macrogen Corp. in the US was established. In 2012, Macrogen Corp. was established to provide advanced clinical sequencing services to U.S. patients and hospitals. In that time, we’ve become a leading bioscience research firm and our reputation in the industry is proof of our commitment to advanced human genomic sequencing.
As a CLIA-licensed research facility, we offer highly specialized sequencing services, utilizing the latest the latest next-generation sequencing. Additionally, the Macrogen team employs highly trained researchers who are the experts in their fields. Our next-generation sequencing services have been utilized by researchers from many prestigious institutions, including but not limited to: National Institute of Health (NIH), Food and Drug Administration (FDA), Stanford University, etc.